AbbVie Acquires Allergan for US$63 B to Ease Humira Fears

By Michelle Liu

Pharma Deals Review: Vol 2019 Issue 7 (Table of Contents)

Published: 2 Jul-2019

DOI: 10.3833/pdr.v2019.i7.2438     ISSN: 1756-7874

Section: Mergers & Acquisitions



In the second largest M&A deal of 2019 so far, AbbVie has agreed to acquire Allergan for approximately US$63 B in an effort to ease investor concerns regarding AbbVie’s over-reliance on Humira® (adalimumab)...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details